These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 37179582)

  • 1. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
    Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
    World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT.
    Duan M; Xiao H; Shi M; Xie Y; Zhao P; Li S; Chi X; Liu X; Zhuang H
    BMC Infect Dis; 2024 Jul; 24(1):723. PubMed ID: 39044129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-normal alanine aminotransferase is an indicator for liver histopathology in HBeAg-negative chronic hepatitis B.
    Duan M; Chi X; Xiao H; Liu X; Zhuang H
    Hepatol Int; 2021 Apr; 15(2):318-327. PubMed ID: 33638049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lower HBV DNA level is associated with more severe liver fibrosis in HBeAg-positive chronic hepatitis B with normal alanine transaminase.
    Wang J; Zhu L; Zhang Z; Zhang S; Pan Y; Li Y; Cao F; Jiang C; Fan T; Xiong Y; Liu J; Chen Y; Yin S; Tong X; Zhu C; Liu X; Li J; Wu C; Huang R
    Virol J; 2024 Jun; 21(1):127. PubMed ID: 38835029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discriminant value of serum HBV DNA levels as predictors of liver fibrosis in chronic hepatitis B.
    Sanai FM; Helmy A; Bzeizi KI; Babatin MA; Al-Qahtani A; Al-Ashgar HA; Al-Mdani AS; Al-Akwaa A; Almutharea S; Khan MQ; Alghamdi AS; Farah T; Al-Hamoudi W; Saadeh M; Abdo AA
    J Viral Hepat; 2011 Jul; 18(7):e217-25. PubMed ID: 21692936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liver fibrosis progression is uncommon in patients with inactive chronic hepatitis B: a prospective cohort study with paired transient elastography examination.
    Wong GL; Chan HL; Yu Z; Chan HY; Tse CH; Wong VW
    J Gastroenterol Hepatol; 2013 Dec; 28(12):1842-8. PubMed ID: 23829381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase.
    Gao Y; Wang M; Liu X
    Microbiol Spectr; 2024 Apr; 12(4):e0394123. PubMed ID: 38426768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HBV DNA level could predict significant liver fibrosis in HBeAg negative chronic hepatitis B patients with biopsy indication.
    Praneenararat S; Chamroonkul N; Sripongpun P; Kanngurn S; Jarumanokul R; Piratvisuth T
    BMC Gastroenterol; 2014 Dec; 14():218. PubMed ID: 25523185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nucleos(t)ide Analogue Treatment for Patients With Hepatitis B Virus (HBV) e Antigen-Positive Chronic HBV Genotype C Infection: A Nationwide, Multicenter, Retrospective Study.
    Chang Y; Choe WH; Sinn DH; Lee JH; Ahn SH; Lee H; Shim JJ; Jun DW; Park SY; Nam JY; Cho EJ; Yu SJ; Lee DH; Lee JM; Kim YJ; Kwon SY; Paik SW; Yoon JH
    J Infect Dis; 2017 Dec; 216(11):1407-1414. PubMed ID: 29029102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    Chakrabarty G; Bruce M; Horner M; Wang B; Agarwal K; Carey I
    J Viral Hepat; 2018 Jan; 25(1):80-87. PubMed ID: 28710798
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the change in antiviral therapy indication on identifying significant liver injury among chronic hepatitis B virus infections in the grey zone.
    Ren S; Wang W; Lu J; Wang K; Ma L; Zheng Y; Zheng S; Chen X
    Front Immunol; 2022; 13():1035923. PubMed ID: 36389814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of hepatocarcinoma-related hepatitis B virus mutants in patients in grey zone of treatment.
    Gil-García AI; Madejón A; Francisco-Recuero I; López-López A; Villafranca E; Romero M; García A; Olveira A; Mena R; Larrubia JR; García-Samaniego J
    World J Gastroenterol; 2019 Oct; 25(38):5883-5896. PubMed ID: 31636479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Demographic characteristics and associated influencing factors in treated patients with chronic hepatitis B with hypoviremia : a single-center retrospective cross-sectional study].
    Li T; Kong Y; Liu YY; Liu TF; Ma AD; Li LQ; Pei ZY; Zhang LY
    Zhonghua Gan Zang Bing Za Zhi; 2023 Jan; 31(1):42-48. PubMed ID: 36948848
    [No Abstract]   [Full Text] [Related]  

  • 17. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High prevalence of significant histology in asymptomatic chronic hepatitis B patients with genotype C and high serum HBV DNA levels.
    Park JY; Park YN; Kim DY; Paik YH; Lee KS; Moon BS; Han KH; Chon CY; Ahn SH
    J Viral Hepat; 2008 Aug; 15(8):615-21. PubMed ID: 18573162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of liver biopsy on the decision to treat patients with chronic hepatitis B genotype D virus infection.
    Al-Qahtani AA; Al-Ashgar HI; Al Mana H; Al-Ahdal MN; Soliman Ali A; Hasanain AF; Helmy A
    Intervirology; 2014; 57(5):248-53. PubMed ID: 24993859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. East Asia expert opinion on treatment initiation for chronic hepatitis B.
    Kao JH; Hu TH; Jia J; Kurosaki M; Lim YS; Lin HC; Sinn DH; Tanaka Y; Wai-Sun Wong V; Yuen MF
    Aliment Pharmacol Ther; 2020 Nov; 52(10):1540-1550. PubMed ID: 32951256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.